<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="468">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409030</url>
  </required_header>
  <id_info>
    <org_study_id>RH-VAL-2013-01</org_study_id>
    <nct_id>NCT02409030</nct_id>
  </id_info>
  <brief_title>Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease</brief_title>
  <acronym>RH-VAL</acronym>
  <official_title>Validation Trial for a Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raman Health Technologies, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Raman Health Technologies, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate a diagnostic test that combines different blood&#xD;
      markers to identify and correctly classify patients with Alzheimer's disease (AD) compared to&#xD;
      individuals with behavioural variant frontotemporal dementia (bvFTD, patient control) versus&#xD;
      cognitively healthy individuals (healthy control).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to validate a new multi-parameter diagnostic test, on a&#xD;
      well-characterised population based on new AD diagnostic criteria, that combines different&#xD;
      types of markers, selected based on prior exploratory studies carried out by Raman Health&#xD;
      Technologies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">October 18, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood markers</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Multi-parameter determination: Raman laser and infrared spectroscopic markers, Metabolite-based markers (A02, A16, A22 ST01 F20 M30), Protein markers (A, A-T, B, PRO-B, C, C1, C2, PROGRANULIN), Biochemical markers (OXIDATIVE STRESS MARKERS, CTAN, ROUTINE BIOCHEMICAL MARKERS (GLUCOSE, TRIGLYCERIDES) and Genetic markers (ApoE, ApoC).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cognitively Healthy controls</arm_group_label>
    <description>The neuropsychological test assessment must confirm that there is no cognitive impairment.&#xD;
In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <description>Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal dementia</arm_group_label>
    <description>Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      3 tubes of blood ( 30 mL of blood in total) for further analysis of their products (plasma,&#xD;
      cells and DNA) in Alzheimer's research unit project CIEN Foundation would be extracted .&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        It is estimated that a sample of 500 patients (250 with AD and 250 with FTD) and 200&#xD;
        controls (700 individuals in total) will be sufficient to corroborate the hypothesis that&#xD;
        permits validation of the new diagnostic test. The sample size estimate is based on a&#xD;
        hypothesis of non inferiority between the new test and the test used in normal clinical&#xD;
        practice, expecting a 10% delta of the 75% validity, sensitivity and specificity indices&#xD;
        with an alpha error of 0.05 and a beta error of 0.20.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy controls:&#xD;
&#xD;
               -  Aged between 50-80 years.&#xD;
&#xD;
               -  Men and women.&#xD;
&#xD;
               -  Assessment of the neuropsychological tests confirming the absence of cognitive&#xD;
                  impairment.&#xD;
&#xD;
               -  Prior to participant inclusion, obtaining the results of the CerebroSpinal Fluid&#xD;
                  marker analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 24&#xD;
                  months before recruitment.&#xD;
&#xD;
          2. Patients diagnosed with Alzheimer's disease (AD).&#xD;
&#xD;
               -  Aged between 50-80 years.&#xD;
&#xD;
               -  Men and women.&#xD;
&#xD;
               -  Patients meet the clinical criteria for Alzheimer's disease:&#xD;
&#xD;
               -  Prior to participant inclusion, results obtained from CerebroSpinal Fluid marker&#xD;
                  analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 36 months&#xD;
                  before recruitment.&#xD;
&#xD;
          3. Patients with behavioural variant frontotemporal dementia and primary progressive&#xD;
             aphasia: -&#xD;
&#xD;
               -  Aged between 50-80 years.&#xD;
&#xD;
               -  Men and women.&#xD;
&#xD;
               -  Patient meets the clinical criteria of behavioural variant frontotemporal&#xD;
                  dementia (bvFTD), or syndromes associated with temporal variants that affect&#xD;
                  language (primary progressive aphasia, agrammatic and semantic subgroups):&#xD;
&#xD;
        (Mild Cognitive Impairment) sub-study: Patients with mild cognitive impairment will be&#xD;
        included&#xD;
&#xD;
          -  Aged between 50-80 years.&#xD;
&#xD;
          -  Men and women.&#xD;
&#xD;
          -  Patient meets the clinical criteria for mild cognitive impairment:&#xD;
&#xD;
          -  Clinical diagnostic criteria for mild cognitive impairment: NIA-Alzheimer's&#xD;
             Association of America criteria, Alzheimer's Dementia, 2011&#xD;
&#xD;
          -  Prior to participant inclusion, results obtained from cerebrospinal fluid marker&#xD;
             analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 12 months before&#xD;
             recruitment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe or acute systemic disease that could impede the participant's follow-up study:&#xD;
             Advanced liver or kidney disease and disseminated neoplastic disease&#xD;
&#xD;
          -  Addiction to alcohol or other drugs in the last two years based on Diagnostic and&#xD;
             Statistical Manual of Mental Disorders IV criteria, except nicotine use, which is&#xD;
             permitted&#xD;
&#xD;
          -  Down's syndrome&#xD;
&#xD;
          -  Moderate or severe head injury&#xD;
&#xD;
          -  central nervous system infections (HIV, syphilis, borrelia, herpes simplex, suspected&#xD;
             Creutzfeldt-Jakob disease)&#xD;
&#xD;
          -  Endocrine alterations (thyroid alterations)&#xD;
&#xD;
          -  Nutritional deficiency (vitamin B12, folic acid)&#xD;
&#xD;
          -  Clinical history of stroke in the previous three months or neuroimaging evidence of&#xD;
             clinically significant cardiovascular disease (e.g. strategic infarct or severe&#xD;
             leukoencephalopathy).&#xD;
&#xD;
          -  Neurological diseases (dysmyelinating disorders, Parkinson's disease, Huntington's&#xD;
             disease, normal pressure hydrocephalus, subdural haematoma, brain tumours)&#xD;
&#xD;
          -  Major psychiatric disorder (major depression or psychosis)&#xD;
&#xD;
          -  Patients who do not have a clearly defined clinical diagnosis according to the study&#xD;
             groups (inclusion/exclusion criteria)&#xD;
&#xD;
          -  Disease which, in the investigator's or sponsor's judgement, may have a potentially&#xD;
             significant influence and thus generate bias in the study markers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Cabello</last_name>
    <role>Study Director</role>
    <affiliation>Raman Health Technologies, S.L.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL St Luc</name>
      <address>
        <city>Brussel</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'ARRAS</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Neurologique CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Mémoire paris Nord Ile de France GH Saint-Louis Lariboisière Fernand Widal</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive and Behavioral Disease Center and Alzheimer's Institute</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITA Alzheimer</name>
      <address>
        <city>Donostia / San Sebastián</city>
        <state>San Sebastián</state>
        <zip>20009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

